|
|
Article: Xencor Initiates Phase I Clinical Trial with XmAb2513 in Lymphoma.
- Article from:
- Business Wire
- Article date:
- February 11, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
MONROVIA, Calif. -- Xencor, Inc., a company developing protein and antibody therapeutics, has initiated a Phase I clinical trial with its lead product candidate XmAb[TM]2513 in patients with Hodgkin lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL). XmAb2513 is a humanized monoclonal antibody that targets the antigen CD30. It is engineered to contain an XmAb[TM] Fc domain using Xencor's Protein Design Automation([R]) platform technology to greatly increase its cytotoxic potency.
The open-label, dose escalation study is designed to define the recommended dose of XmAb2513 for subsequent trials, to determine its safety and tolerability, characterize ...